Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07513454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of HW211026

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 2026 to Jul 2026 Eligibility criteria expanded, about 21 words · Study title shortened, about 5 wordsv2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 21 words
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Trial Details
NCT Number NCT07513454
Lead Sponsor Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Conditions Actinic Keratosis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov